

Detection of a novel mutation G511T in the 530 loop in 16S rRNA in multi drugs resistant Mycobacterium tuberculosis isolated from Sudanese patients

Yousif Mohammed Alfatih,^{1,*,#} Abeer Babiker Idris,^{2,3,*} Hadeel Gassim Hassan,^{2,3} Eman O M. Nour,⁴ Nihad M A. Elhaj,⁵ Salah-Eldin El-Zaki,⁶ Muataz M. Eldirdery,⁵ Rahma H. Ali,⁴ Nuha Y. Ibrahim,⁴ Asrar M Elegail,⁴ Mohamed Ahmed Salih.³

¹Department of Microbiology, Faculty of medical laboratory Science, Sudan international University, Khartoum-Sudan

²Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum-Sudan

³Department of Bioinformatics, Africa city of technology, Khartoum-Sudan

⁴National Tuberculosis Reference Laboratory-National Laboratory of Public Hospital, Khartoum-Sudan

⁵Tropical Medicine Research Institute-National Center for Research, Khartoum-Sudan

⁶Department of Epidemiology, Molecular Epidemiology Laboratory, Tropical Medicine Research Institute, Khartoum, Sudan.

* Contributed equally

#Corresponding author: tofi56478@gmail.com

Abstract

Background: Tuberculosis (TB) is a bacterial disease considered as a global public health emergency by the World Health Organization (WHO) since 1993. In Sudan, MDR-TB represents a growing threat and one of the most important challenges that faced national tuberculosis program to establish a comprehensive multidrug-resistant tuberculosis management system.

Objective: To characterize the diversity and frequency of mutations in Sudanese MDR-TB strains isolated from Wad Madani, Al-Gadarif and Khartoum using 16S rRNA and phylogeny approach.

Material and Methods: A total of 60 MDR-TB isolates from Wad-Madani, Al-Gadarif and Khartoum were tested with molecular LPA (Genotype MTBDR plus) and GeneXpert MTB/RIF assay and Spoligotyping to confirm their resistance to RIF and INH. Sequencing and phylogenetic analysis was carried out using in silico tools.

Result: This study revealed the circulation of different Sudanese MDR-TB strains isolated from Wad Madani and Al-Gadarif belonging to two distinct common ancestors. Two isolates from Wad Madani (isolate3 and isolate11) found in one main group which characterized by a novel mutation G511T in the 530 loop.

Conclusion: The recurrence of C217A mutation in Wad Madani (isolate11) indicates the spread of this mutation in Sudanese MDR-TB strains and the diversity of this inheritance leading to generate new G511T novel mutation. So, understanding the molecular characterization of resistance mechanisms in MD-TB can facilitate the early detection of resistance, the choice of appropriate treatment and ultimately the management of MD-TB transmission. Bioinformatics approaches provide helpful tools for analyzing molecular mechanisms of resistance in pathogens.

Keywords: Tuberculosis (TB), Multidrug-resistant TB (MDR-TB), 16S rRNA, in silico tools.

1. Introduction

Tuberculosis (TB) is a bacterial disease considered as a global public health emergency by the World Health Organization (WHO) since 1993 (1-3). It is the ninth leading cause of death worldwide, with a mortality ranging from 1.6 to 2.2 million per year (4, 5), and the leading cause from a single infectious agent, ranking above HIV/AIDS (5-8). However, most deaths from TB could be prevented with early diagnosis and appropriate treatment. According to the global tuberculosis report 2017 which has been published by WHO, In 2016, there were 600 000 new cases with resistance to rifampicin the most effective first-line drug, of which 490 000 had multidrug-resistant TB (MDR-TB) and the treatment remains low globally (5). In Sudan as in other developing countries, MDR-TB represents a growing threat and one of the most important challenges that faced national tuberculosis program to establish a comprehensive multidrug-resistant tuberculosis management system (9, 10).

Multidrug-resistant TB (MDR-TB) is defined as resistance to first-line anti-TB drugs such as Rifampicin (RIF), which is the most effective drug against TB and considered as a broad spectrum antimicrobial (11-14). and isoniazid (INH) drug which has the most powerful bactericidal activity against TB and has good tolerance and low price (14). Multi Drug-resistant *Mycobacterium tuberculosis* has been reported in the early days of the introduction of drug therapy (15). Grasp the molecular basis of resistance can lead to the development of novel rapid methods for the diagnosis of MDR-TB (16). In addition to highly conserved primer binding sites, 16s ribosomal RNA gene (16S rRNA) sequences contain hyper variable regions that can provide species-specific signature sequences useful for identification of uncharacterized MDR-TB (17, 18). as a result, 16S rRNA gene sequencing has become prevalent in medical microbiology as a rapid and cheap alternative to phenotypic methods of bacterial identification (19, 20). Although it was originally used to identify bacteria, 16S sequencing was subsequently found to be capable of reclassifying bacteria into completely new species or even genera (21, 22). It has also been used to characterize new species that difficult been successfully cultivated in vitro (23, 24).

As long as MDR-TB is not verified, use of inadequate management and hence ineffective antibiotics may lead to further spread of uncharacterized resistant bacteria and amplification of resistance(25, 26). Smear microscopy has long been known as the primary method for screening of TB, with a case detection rate of not more than 68% (27). Marked instance of TB misdiagnosis was evident in 2010 where 2 million of the 5.8 million (34.4%) globally notified cases were found to be smear negative (28). However, the time for bacteriological culture-based diagnosis of TB may require several weeks to months so the rapid and sensitive method will be required for good and safety management (29-31). Therefore, the aims of the current study were to analyze the molecular characterization of Sudanese MDR-TB strains isolated from Al-khartoum, Al-Gadarif and Wad-Madani States using 16S rRNA. Also, to determine the frequency of mutations in 16S rRNA among them. To our knowledge no previous study has reported the sequencing of 16S rRNA in order to study the diversity and frequency of *rrs* mutations among Sudanese strains isolated from Al-Gadarif and Wad-Madani States.

2. Material and methods

2.1 Ethical consideration

This study was approved by the National center for research ethical committee and the Ethics Committee of the Sudan international University -Khartoum, Sudan.

2.2 Study design and study setting

A cross-sectional descriptive study was conducted at the National Public Health Laboratory, Khartoum, Sudan. A total of 60 MDR-TB isolates from Wad-Madani, Al-Gadarif and Khartoum (Figure1), were tested with molecular LPA (Genotype MTBDRplus) and GeneXpertMTB/RIFassay and Spoligotyping (32, 33) to confirm their resistance to RIF and INH. All sample show positive MDR-TB.

2.3 Molecular analysis

2.3.1 GenoLyse Extraction Method

DNA extraction was performed as recommended by (Hain Lifescience) manufacturer. The first step was to heat the isolate in a water bath for 30 minutes at 100°C and then suspended in 100ul of kit lysis buffer followed by incubation at 95°C for 5 min the last step addition of 100ul neutralization buffer. The mixture was spun at full speed in a tabletop centrifuge with an aerosol tight rotor. The extracted DNA were then stored at -20°C (34).

2.3.2 PCR for 16s rRNA gene

Twenty genomic DNA were used as templates for PCR amplification of complete *rrs* gene (16SrRNA). The two primers used were forward primer, 27F(5-AGAGTTTGATCCTGGCTCAG-3) and reverse primer, 1495R(5-CTACGGCTACCTTGTTACGA-3). The 25ul reaction mixture contained 5ul DNA, 2.5ul reaction buffer (10x) with 1.5ul MgCl₂, 0.5ul Taq DNA polymerase (5 U/ul) 0.625ul dNTPs, 1ul of 10 pmol of each primer, and 1x of gel loading buffer, followed by completing the volume to 12.875ul by DW. PCR amplifying procedure was as follows: Initial Melting (5 min at 94°C), 30 cycles as follow: Melting (1 min at 94°C), Annealing (1 min at 58°C) and Extension (2 min at 72°C) then final Extension (10 min at 72°C), which was performed on a Bio-Rad (DNA engine/Dyad Peltier) automatic thermal cycler. The products of amplification were checked through running on 0.6% agarose gel electrophoresis (35). The PCR product for *rrs*gene was (1500pb). (Figure 2a)

2.4 Sequencing of 16S rRNA

PCR products of 15 isolates were packaged according to the International Air Transport Association guidelines and shipped with authorized permission to Macrogen Company (Seoul, South Korea) for BGI Sanger Sequencing. Sequencing for both forward and reverse nucleotide sequencing was carried out.

2.5 Bioinformatics analysis

The chromatogram files of sequencing results were viewed and checked for quality by Finch TV program version 1.4.0(36). The Basic Local Alignment Search Tool (BLAST; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>)(37) was used to search highly similar sequences available in GenBank database which retrieved from NCBI(38). Then BioEdit software (39) was used to align the similar sequences and the phylogenetic analysis was performed using the online server Phylogeny.fr (<http://www.phylogeny.fr/>) (40).

2.6 statistical Analysis

The results were analyzed statistically using Graph Pad Prism (version 5.0) which is a commercial scientific 2D graphing and statistics software(41).

3. Results

3.1 Demographic characteristic of patients

Among 60 patients who infected with RIF and INH resistant *M. tuberculosis* isolates, were selected in this study, 32(53.3%) of them were males while females represented 28(46.7%). The highest percentage of MDR-TB was found in the age group ranged between 31-59 years 38(63.3%) while the lowest in the age group ≥ 60 years 3(5%), as illustrated in Table 1.

3.2 Bioinformatics analysis result

From 15 chromatograms, only five showed high quality by FinchTV. BLAST analysis of their sequences showed 99% identity to 16s rRNA gene nucleotide sequences of different MDR-TB strains isolated from different countries, that obtained from GenBank databases, accession numbers of 16s rRNA gene nucleotide sequences of MDR-TB retrieved strains and their area of collections are listed in Table 2.

The multiple sequence alignment of the 5 Sudanese MDR-TB *rrs* genes nucleotide sequences with the similar nucleotide sequences that obtained from BLAST was carried out, to find the homology and evolutionary relation between these sequences, by BioEdit software; after checking the identities and differences we found that two isolates from Wad Madani (isolate3 and isolate11) had a novel mutation, G→T transversion at nucleoside position 511, in the 530 loop. Al-gadarif's isolate (isolate17) showed C→A transversion at nucleoside position 217. Another novel mutation, G→A transition at nucleoside position148, was found in two isolates (isolate2 and isolate3) from Wad Madani. However, isolate3 harbored another third novel mutation, G→T transversion at nucleotide position 736. The phylogenetic tree assimilates and represents the result of relationship between the Sudanese isolates and GenBank series of *Mycobacterium tuberculosis* stains (Figure 2).

4. Discussions

The 16S rRNA is the most common housekeeping genetic marker, so its sequences are used to study bacterial phylogeny and taxonomy (42). In this study, we used the 16S rRNA sequencing in order to characterize the diversity and frequency of mutations in Sudanese strains isolated from Wad Madani and Al-gadarif which revealed the circulation of different strains belonging to two distinct common ancestors. Two isolates from Wad Madani (isolate3 and isolate11) found in one main group which characterized by a novel mutation G511T in the 530 loop. while other isolates from Wad Madani with Al-gadarif's isolate (isolate17) were clustered in one group and showed close similarity to strains from different part of the world (Figure 2e)

Streptomycin was the first aminoglycoside which discovered in the 1940s. It inhibits initiation of mRNA translation.(43) The rapid emergence of resistant mutants with relatively high frequency among microorganisms has greatly reduced its therapeutic effectiveness. So, Streptomycin should not be used alone to treat any infection. it is used in combination with other anti-tuberculous drugs (INH, rifampin) to treat tuberculosis.(44) In tuberculosis, the high level of resistance against Streptomycin results from missense mutations in the genes *rrs* and *rpsL* which encoding two components of the ribosome, the 16S rRNA and the S12 protein, respectively.(45) when streptomycin-resistant strains with wild-type S12 proteins were found, the resistance has been attributed to mutations in *rrs* affecting one of two highly conserved loops that are adjacent in the 16S rRNA, the regions around nucleotide 904 and the 530 loop.(46) However, about one-third of streptomycin-resistant isolates do not have mutations in the *rrs* or *rpsL* genes.(47)

In this study, we found a novel mutation, G→T transversion at nucleoside position 511, in the 530 loop while alterations at positions 491, 512, 516 were not found.(48-50) Also, the insertion of cytosine residue between nucleotides 512 and 513, which had previously been reported to confer both streptomycin resistance and dependence, was not detected.(6) However, this finding is in agreement with another study done by Katsukawaet al. in Japan which found a novel

mutation, at that time, at position 513 (A:C, A:T) and also they found no mutations at positions 491, 512, 516, 904, 905 or base insertion between 512 and 513.(47) in contrast, there are another studies conducted in Khartoum state by Solima *et al.*(51), in Poland by Brzostek *et al.*(52) and in New York City by Cooksey *et al.*(43) revealed no mutations in the 530 loop. Another novel mutation, G→A transition at nucleoside position148, was found in two isolates (isolate2 and isolate3) from Wad Madani. It is interesting to note that isolate3 harbored another third novel mutation, G→T transversion at nucleotide position 736, so it belonged to distinct common ancestor along with isolate11 that had one of these novel mutations G115T. Further studies are needed for in vitro phenotypic resistance with large sample size to confirm the association between these novel mutations and phenotypic Streptomycin-resistance and reliability of these mutations as molecular markers of resistance.

Moreover, Al-gadarif's isolate showed C217A mutation which is the same novel mutation reported from Streptomycin resistance Sudanese strains in Khartoum state.(51) Regarding the region centered around nucleotide 912, which may form part of a site involved in codon-anti-codon interaction and proofreading(49), there is no mutation was observed which is in accordance with other studies conducted in Barcelona,(53) China,(54) Germany(49) and in Latvia.(55) This accordance could indicate that mutations in the *rrs* 912 region are not common.

Conclusion

The recurrence of C217A mutation in Wad Madani (isolate11) indicate the spread of this mutation in Sudanese MDR-TB strains and the diversity of this inheritance leading to generate new G511T novel mutation. So, understanding the molecular characterization of resistance mechanisms in MD-TB can facilitate the early detection of resistance, the choice of appropriate treatment and ultimately the management of MD-TB transmission. Bioinformatics approaches provide helpful tools for analyzing molecular mechanisms of resistance in pathogens.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

The authors are grateful to Tropical Medicine Research Institute, Total Lab care Laboratories, Molecular Tuberculosis Reference Laboratory, Africa City of Technology, and all members of the National Reference Laboratory of Tuberculosis (NRL-TB), Sudan, Khartoum.

References:

1. Abdallah TM AA. Epidemiology of tuberculosis in Eastern Sudan. *Asian Pacific Journal of Tropical Biomedicine*. 2012;2(12)::999-1001.
2. Who WHO. Global tuberculosis report 2013. Geneva, Switzerland. 2013.
3. Lewandowski CMC-i, NewLewandowski,. WHO Global tuberculosis report. who. 2015.
4. E JAC. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis pubmed. 2013.
5. WH.; O. Global tuberculosis report Geneva, Switzerland WHO Report]. Available from: http://www.who.int/tb/publications/global_report/en/2017
6. WHO. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland Available from :<http://whqlibdoc.who.int/publications/2010>
7. Organization WH. Global tuberculosis report 2017 Geneva, Switzerland: WHO; 2017 [cited 2017 21]. Report]. Available from: http://www.who.int/tb/publications/global_report/en/.
8. Nunn P WB, Floyd K, Dye C, Elzinga G. Raviglione M. tuberculosis control in the era of HIV. *Nat Rev Immunol*. 2015;5(819–26).
9. WHO.]. Tuberculosis in the Eastern Mediterranean Region [Internet]. Available from: https://extranet.who.int/iris/restricted/bitstream/10665/254895/1/EMROPUB_2017_EN_19610pdf?ua=1&ua=1. 2015.
10. Organisation W. WHO Report 2010. Global tuberculosis control 2010.
11. E JAC. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. International Union Against Tuberculosis and Lung Disease. 2013.
12. Akter HossainSaurab KM, Farjana Rahman,. Slide drug susceptibility test for the detection of multidrug-resistant tuberculosis. pubMed. 2013.
13. Aurin TH MS, Kamal SM, Rahman MM, Hossain MS,Marma T. I. Molecular approaches for detection of the multi-drug resistant tuberculosis (MDR-TB) in Bangladesh. *PloS one*. 2014;9(6):99810.
14. Somoskovi A1 PL, Salfinger M,. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. pupmed. 2001.
15. Anju Jain SKP. MOLECULAR DIAGNOSIS OF MULTI DRUG RESISTANT TUBERCULOSIS. *International journal of biomedical and advanced research*. 2012.

16. Emler S, NB RP, Auckenthaler R., Jäger D.Eur J Molecular basis for cross-reactivity between a strain of *Mycobacterium terrae* and DNA probes for *Mycobacterium tuberculosis* complex. *Microbial Infect Dis*. 1995.
17. Pereira F CJ MR, van Asch B, Pinto N. Identification of species by multiplex analysis of variable-length sequences. *Nucleic Acids Research*. 2010;38(22)::e203.
18. CP K. Ribosomal DNA sequencing as a tool for identification of bacterial pathogens. *Current Opinion in Microbiology*. 1999;;2(3).
19. C. J. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. *Clinical Microbiology Reviews*. 2004;17(4).
20. Solima M. A. Sabeel, 2 Mohamed Ahmed Salih,3 Manasik Ali,. Phenotypic and Genotypic Analysis of Multidrug-Resistant *Mycobacterium tuberculosis* Isolates from Sudanese Patients. *pubmed*. 2016.
21. SP LT, Oerther DB Reverse transcription of 16S rRNA to monitor ribosome-synthesizing bacterial populations in the environment. *Applied and Environmental Microbiology*. 2009;75(13).
22. Oger P, Dessaux Y, Petit A,. Validity, sensitivity and resolution limit of the PCR-RFLP analysis of the *rrs* (16S rRNA gene) as a tool to identify soil-borne and plant-associated bacterial populations. *Genetics Selection Evolution*. 1998;30(1):S311.
23. Weisburg WG BS PD, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. *Journal of Bacteriology*. 1991;173(2).
24. Paliy O, Brent D. Mathematical modeling of 16S ribosomal DNA amplification reveals optimal conditions for the interrogation of complex microbial communities with phylogenetic microarrays. 2011;27(15):2134-40.
25. Matteelli A, Alberto,Carvalho, Anna C.C. Extensively drug-resistant tuberculosis: Epidemiology and management. *Clinical Epidemiology*. 2014;6(1): 111-8.
26. Chang KC, Wing Wai. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. *Respirology*. 2013;18(1):8-21.
27. Organization WH. Global tuberculosis control: a short update to the 2009 report. *Who*. 2009;9:218.
28. Who. Global Tuberculosis Control. WHO 2010. *who*. 2010:218.
29. Naidoo PD, Rory Lombard. Comparing tuberculosis diagnostic yield in smear/culture and xpert1 MTB/RIF-based algorithms using a non-randomised stepped-wedge design. *PLoS ONE*. 2016;11(3).

30. Chang KCY, Wing Wai. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. *Respirology*. 2013;18(1):8-21.
31. Chiang CYS, H. S. Management of drug-resistant tuberculosis. *International Journal of Tuberculosis and Lung Disease*. 2010;14(6):672-82.
32. Muataz M. Eldirdery IEA, Mona OA. Awad ElkareIm. Genotyping of Pulmonary Mycobacterium tuberculosis Isolates from Sudan Using Spoligotyping. *American Journal of Microbiological Research*. 2015;3(4):125-8.
33. Rahma Hasbelrasoul Ali NYI, Asrar Mohamed Abdalsalam Elegail. Evaluation of GeneXpert MTB/RIF and line probe assay for rapid diagnosis of Mycobacterium tuberculosis in Sudanese pulmonary TB patients. *Asian Pacific Journal of Tropical Disease*. 2017;7(7):426-9.
34. Hain Life Science H, Nehren, Germany, Available from <http://www.hain-lifescience.de>
35. WenjunBao Q, ManjunChen, Xia. Isolation and identification of lactic acid bacteria from Tarag in Eastern Inner Mongolia of China by 16S rRNA sequences and DGGE analysis. *Microbiological Research*. 2012;167(2):110-5.
36. FinchTV. 1.4.0 ed. USA: Geospiza, Inc.; Seattle, WA,; 2012.
37. Altschul SF, Madden TL, Schäffer AA,. Gapped BLAST and PSI-BLAST. A new generation of protein database search programmes. *Nucleic Acids Res*. 1997;25(17):3389–402.
38. L.Geer LYM-B, Aron Geer,. The NCBI BioSystems database. *Nucleic Acids Research*. 2009;38(SUPPL.1).
39. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucl Acids Symp Ser* 1999;41:95-8.
40. Dereeper A, Audic S, Claverie JM, Blanc G. BLAST-EXPLORER helps you building datasets for phylogenetic analysis. *BMC Evol Biol*. 2010;10(8):8.
41. Miller JM. GraphPad PRISM. Analysis. 2003;52(1):2-3.
42. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. *Journal of clinical microbiology*. 2007;45(9):2761-4.
43. Cooksey RC MG, McQueen A, Glickman SE,. Characterization of streptomycin resistance mechanism among Mycobacterium tuberculosis isolates from patients in New York City. *Antimicrobial agents and chemotherapy*. 1996;40(5):1186-8.

44. Geo. F. Brooks, Karen C. Carroll, Janet S. Butel,. Antimicrobial chemotherapy. In: Karen C. Carroll, editor. Jawetz, Melnick & Adelberg's medical microbiology. a LANGE medical book. 26 ed. USA: McGraw-Hill education; 2013. p. 149-403.
45. Wu X-Q, Lu Y, Zhang J-X . Detection of Streptomycin Resistance in Mycobacterium tuberculosis Clinical Isolates Using Four Molecular Methods in China. *Acta Genetica Sinica*. 2006;33(7):655-63.
46. Honore N, Marchal G, Cole ST. Novel mutation in 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis. *Antimicrobial agents and chemotherapy*. 1995;39(3):769-70.
47. Katsukawa C, Tamaru A, Miyata Y,. Characterization of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan. *J Appl Microbiol*. 1997;83(5):634-40.
48. Meier A, Kirschner P, Bange FC,. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. *Antimicrobial agents and chemotherapy*. 1994;38(2):228-33.
49. Finken M, Kirschner P, Meier A,. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. *Molecular Microbiology*. 1993;9(6):1239-46.
50. Cuevas-Cordoba B, Cuellar-Sanchez A, Pasissi-Crivelli A, R. rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 2013;46(1):30-4.
51. Sabeel SM, Salih MA, Ali M, El-Zaki SE, Abuzeid N, Elgadi ZA, et al. Phenotypic and Genotypic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Isolates from Sudanese Patients. *Tuberc Res Treat*. 2017;2017:8340746.
52. Brzostek A, Sajduda A, Sliwinski T, Molecular characterisation of streptomycin-resistant Mycobacterium tuberculosis strains isolated in Poland. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2004;8(8):1032-5.
53. Tudo G, Rey E, Borrell S, Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona. *The Journal of antimicrobial chemotherapy*. 2010;65(11):2341-6.
54. Shi R, Zhang J, Li C, Kazumi Y. Detection of streptomycin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by denaturing HPLC analysis and DNA sequencing. *Microbes Infect*. 2007;9(14-15):1538-44.

55. Tracevska T, Jansone I, Nodieva A, Baumanis V. Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis. Res Microbiol. 2004;155(10):830-4.




Figure 1. Frequency of our isolates in the states




Figure 2. (2a) PCR amplification results of *rrs* gene products on 2% agarose gel electrophoresis. Lane 1 DNA ladder: MW100-1500bp fragments. (2b) Sequencing result of the chromatogram using Finch TV software illustrates C217A mutation. (2c) BioEdit multiple sequences alignment determining C217A mutation. (2d) BioEdit multiple sequences alignment determining a novel mutation at position 511. (2e) Phylogenetic tree using Phylogeny.fr software. The 5 nucleotide sequences of the *rrs* genes containing novel mutations were deposited in the GenBank database (National Center for Biotechnology Information; <https://www.ncbi.nlm.nih.gov/>) under the following accession numbers: MG995016 , MG995017 , MG995018 , MG995019 , MG995020.

Table 1. Demographic characteristics of MDR-TB infected patients

Variable	MDR-TB No.(%)
Age	
≤30	19 (31.6%)
31-59	38 (63.3%)
≥60	3 (5%)
Gender	
Male	32 (53.3%)
Female	28 (46.7%)

Table 2. Accession numbers of *rrs* gene nucleotide sequences of MDR-TB retrieved strains and their area of collections

Gene Bank nucleotides accession No.	Country
CP022014	China
CP020381	south-Korea
CP0235801	Peru
CP017597	Colombia
KY810766	Turkey
AP018036	Japan
CP009180	USA
CP009202	USA
CP0237086	India
X52917	Germany